SiSaf’s Bio-Courier Technology Enables Clinical Trial Success for Topical Treatment of Mild to Moderate Alopecia Areata
June 10, 2024 04:00 ET
|
SiSaf Ltd
Positive topline results in a Phase II clinical trial of a licensee’s alopecia treatment using the ProSilic® variant of SiSaf’s Bio-Courier® delivery technology Formulation of the small molecule drug...
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
June 08, 2024 16:30 ET
|
4D Molecular Therapeutics, Inc.
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher...
Nextech Appoints Rusty Frantz as Chief Executive Officer
June 06, 2024 14:00 ET
|
Nextech Systems, Inc.
Nextech, a market leader of technology solutions for specialty physician practices, announced the appointment of Rusty Frantz as Chief Executive Officer.
Active Pharmaceutical Ingredient Market is Expected to Reach $238.3 billion | MarketsandMarkets™
June 06, 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, June 06, 2024 (GLOBE NEWSWIRE) -- Active Pharmaceutical Ingredient market in terms of revenue was estimated to be worth $163.5 billion in 2024 and is poised to reach $238.3 billion by 2029,...
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
June 06, 2024 07:30 ET
|
4D Molecular Therapeutics, Inc.
Clinically meaningful improvements in ppFEV1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment (ppFEV1 50-80%) and >6 months follow up ...
$6.97 Billion Photodynamic Therapy Market Outlook, 2024-2032, Featuring Detailed Analysis of Gladerma, Sun Pharmaceutical Industries, Biofrontera, Lumibird, Bausch Health Companies, and More
June 06, 2024 04:22 ET
|
Research and Markets
Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Photodynamic Therapy Market Report by Product Types, Application, End-user, Countries and Company Analysis 2024-2032" report has been added to ...
Ocular Therapeutix® to Host Investor Day on June 13, 2024
June 05, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD...
Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, June 05, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the...
Hyaluronidase Market is Set to Grow at Staggering CAGR of 9.3% to Reach US$ 1,896.8 Million By 2032 | Astute Analytica
June 04, 2024 13:30 ET
|
AstuteAnalytica India Pvt. Ltd.
New Delhi, June 04, 2024 (GLOBE NEWSWIRE) -- The global hyaluronidase market exhibited a valuation of US$ 852.0 million in 2023, and it is projected to reach a market valuation of US$ 1,896.8...
4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
June 04, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...